全文获取类型
收费全文 | 7044篇 |
免费 | 465篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 162篇 |
妇产科学 | 54篇 |
基础医学 | 377篇 |
口腔科学 | 36篇 |
临床医学 | 355篇 |
内科学 | 2783篇 |
皮肤病学 | 14篇 |
神经病学 | 72篇 |
特种医学 | 297篇 |
外科学 | 2106篇 |
综合类 | 50篇 |
现状与发展 | 1篇 |
预防医学 | 194篇 |
眼科学 | 18篇 |
药学 | 160篇 |
中国医学 | 9篇 |
肿瘤学 | 858篇 |
出版年
2024年 | 5篇 |
2023年 | 531篇 |
2022年 | 862篇 |
2021年 | 710篇 |
2020年 | 665篇 |
2019年 | 467篇 |
2018年 | 380篇 |
2017年 | 397篇 |
2016年 | 315篇 |
2015年 | 341篇 |
2014年 | 729篇 |
2013年 | 521篇 |
2012年 | 251篇 |
2011年 | 93篇 |
2010年 | 255篇 |
2009年 | 229篇 |
2008年 | 58篇 |
2007年 | 90篇 |
2006年 | 80篇 |
2005年 | 75篇 |
2004年 | 30篇 |
2003年 | 49篇 |
2002年 | 46篇 |
2001年 | 44篇 |
2000年 | 43篇 |
1999年 | 37篇 |
1998年 | 49篇 |
1997年 | 38篇 |
1996年 | 39篇 |
1995年 | 45篇 |
1994年 | 26篇 |
1993年 | 19篇 |
1992年 | 13篇 |
1991年 | 10篇 |
1990年 | 1篇 |
1989年 | 8篇 |
1988年 | 9篇 |
1983年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
排序方式: 共有7566条查询结果,搜索用时 62 毫秒
101.
102.
103.
104.
《Diagnostic and interventional imaging》2021,102(12):735-742
PurposeThe purpose of this study was to compare the value of contrast-enhanced computed tomography (CT) to that of magnetic resonance imaging obtained with extracellular contrast agent (ECA-MRI) for the diagnosis of a tumor capsule in hepatocellular carcinoma (HCC) using histopathologic findings as the standard of reference.Materials and methodsThis retrospective study included patients with pathologically-proven resected HCCs with available preoperative contrast-enhanced CT and ECA-MRI examinations. Two blinded radiologists independently reviewed contrast-enhanced CT and ECA-MRI examinations to assess the presence of an enhancing capsule. The histopathological analysis of resected specimens was used as reference for the diagnosis of a tumor capsule. The sensitivity and specificity of CT and ECA-MRI for the diagnosis of a tumor capsule were determined, and an intra-individual comparison of imaging modalities was performed using McNemar test. Inter-reader agreement was assessed using Kappa test.ResultsThe study population included 199 patients (157 men, 42 women; mean age: 61.3 ± 13.0 [SD] years) with 210 HCCs (mean size 56.7 ± 43.7 [SD] mm). A tumor capsule was present in 157/210 (74.8%) HCCs at histopathologic analysis. Capsule enhancement was more frequently visualized on ECA-MRI (R1, 68.6%; R2, 71.9%) than on CT (R1, 44.3%, P < 0.001; R2, 47.6%, P < 0.001). The sensitivity of ECA-MRI was better for the diagnosis of histopathological tumor capsule (R1, 76.4%; R2, 79.6%; P < 0.001), while CT had a greater specificity (R1, 84.9%; R2, 83.0%; P < 0.001). Inter-reader agreement was moderate both on CT (kappa = 0.55; 95% confidence interval [CI]: 0.43–0.66) and ECA-MRI (kappa = 0.57; 95% CI: 0.45–0.70).ConclusionCapsule enhancement was more frequently visualized on ECA-MRI than on CT. The sensitivity of ECA-MRI was greater than that of CT, but the specificity of CT was better than that of ECA-MRI. 相似文献
105.
106.
107.
《Seminars in hematology》2018,55(3):167-175
Paroxysmal nocturnal hemoglobinuria (PNH) is widely regarded as an archetypal complement-mediated disorder that has propelled complement drug discovery in recent decades. Its pathology is driven by chronic complement dysregulation resulting from the lack of the glycosyl phosphatidyl inositol-linked regulators DAF and CD59 on susceptible erythrocytes. This complement imbalance fuels persistent C3 activation on affected erythrocytes, which culminates in chronic complement-mediated intravascular hemolysis. The clinical application of eculizumab, a humanized anti-C5 antibody that blocks terminal pathway activation, has led to drastic improvement of therapeutic outcomes but has also unveiled hitherto elusive pathogenic mechanisms that are now known to contribute to the clinical burden of a significant proportion of patients with PNH. These emerging clinical needs have sparked a true resurgence of complement therapeutics that offer the promise of even more effective, disease-tailored therapies for PNH. Here, we review the current state of complement therapeutics with a focus on the clinical development of C3-targeted and alternative pathway-directed drug candidates for the treatment of PNH. We also discuss the relative advantages and benefits offered by each complement-targeting approach, including translational considerations that might leverage a more comprehensive clinical intervention for PNH. 相似文献
108.
109.
110.